Literature DB >> 21910946

Chronic (-)-epicatechin improves vascular oxidative and inflammatory status but not hypertension in chronic nitric oxide-deficient rats.

Manuel Gómez-Guzmán1, Rosario Jiménez, Manuel Sánchez, Miguel Romero, Francisco O'Valle, Rocío Lopez-Sepulveda, Ana María Quintela, Pilar Galindo, María José Zarzuelo, Elvira Bailón, Eva Delpón, Francisco Perez-Vizcaino, Juan Duarte.   

Abstract

The present study analysed the effects of the flavanol (-)-epicatechin in rats after chronic inhibition of NO synthesis with NG-nitro-L-arginine methyl ester (L-NAME), at doses equivalent to those achieved in the studies involving human subjects. Wistar rats were randomly divided into four groups: (1) control-vehicle, (2) L-NAME, (3) L-NAME-epicatechin 2 (L-NAME-Epi 2) and (4) L-NAME-epicatechin 10 (L-NAME-Epi 10). Rats were daily given by oral administration for 4 weeks: vehicle, (-)-epicatechin 2 or 10 mg/kg. Animals in the L-NAME groups daily received L-NAME 75 mg/100 ml in drinking-water. The evolution in systolic blood pressure and heart rate, and morphological and plasma variables, proteinuria, vascular superoxide, reactivity and protein expression at the end of the experiment were analysed. Chronic (-)-epicatechin treatment did not modify the development of hypertension and only weakly affected the endothelial dysfunction induced by L-NAME but prevented the cardiac hypertrophy, the renal parenchyma and vascular lesions and proteinuria, and blunted the prostanoid-mediated enhanced endothelium-dependent vasoconstrictor responses and the cyclo-oxygenase-2 and endothelial NO synthase (eNOS) up-regulation. Furthermore, (-)-epicatechin also increased Akt and eNOS phosphorylation and prevented the L-NAME-induced increase in systemic (plasma malonyldialdehyde and urinary 8-iso-PGF2α) and vascular (dihydroethidium staining, NADPH oxidase activity and p22phox up-regulation) oxidative stress, proinflammatory status (intercellular adhesion molecule-1, IL-1β and TNFα up-regulation) and extracellular-signal-regulated kinase 1/2 phosphorylation. The present study shows for the first time that chronic oral administration of (-)-epicatechin does not improve hypertension but reduced pro-atherogenic pathways such as oxidative stress and proinflammatory status of the vascular wall induced by blockade of NO production.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21910946     DOI: 10.1017/S0007114511004314

Source DB:  PubMed          Journal:  Br J Nutr        ISSN: 0007-1145            Impact factor:   3.718


  16 in total

1.  (-)-Epicatechin administration and exercising skeletal muscle vascular control and microvascular oxygenation in healthy rats.

Authors:  Steven W Copp; Tadakatsu Inagaki; Michael J White; Daniel M Hirai; Scott K Ferguson; Clark T Holdsworth; Gabrielle E Sims; David C Poole; Timothy I Musch
Journal:  Am J Physiol Heart Circ Physiol       Date:  2012-11-09       Impact factor: 4.733

2.  Ablation of eNOS does not promote adipose tissue inflammation.

Authors:  Thomas J Jurrissen; Ryan D Sheldon; Michelle L Gastecki; Makenzie L Woodford; Terese M Zidon; R Scott Rector; Victoria J Vieira-Potter; Jaume Padilla
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2016-02-10       Impact factor: 3.619

Review 3.  Racial disparities in cardiovascular disease risk: mechanisms of vascular dysfunction.

Authors:  R Matthew Brothers; Paul J Fadel; David M Keller
Journal:  Am J Physiol Heart Circ Physiol       Date:  2019-08-09       Impact factor: 4.733

Review 4.  ( -)-Epicatechin and cardiometabolic risk factors: a focus on potential mechanisms of action.

Authors:  Ezequiel J Hid; Juana I Mosele; Paula D Prince; Cesar G Fraga; Monica Galleano
Journal:  Pflugers Arch       Date:  2021-11-23       Impact factor: 3.657

5.  Changes to the gut microbiota induced by losartan contributes to its antihypertensive effects.

Authors:  Iñaki Robles-Vera; Marta Toral; Néstor de la Visitación; Manuel Sánchez; Manuel Gómez-Guzmán; Raquel Muñoz; Francesca Algieri; Teresa Vezza; Rosario Jiménez; Julio Gálvez; Miguel Romero; Juan Miguel Redondo; Juan Duarte
Journal:  Br J Pharmacol       Date:  2020-02-03       Impact factor: 8.739

6.  Epicatechin's cardiovascular protective effects are mediated via opioid receptors and nitric oxide.

Authors:  Kirsty MacRae; Kylie Connolly; Rebecca Vella; Andrew Fenning
Journal:  Eur J Nutr       Date:  2018-05-10       Impact factor: 5.614

Review 7.  Current status of NADPH oxidase research in cardiovascular pharmacology.

Authors:  Bruno K Rodiño-Janeiro; Beatriz Paradela-Dobarro; María Isabel Castiñeiras-Landeira; Sergio Raposeiras-Roubín; José R González-Juanatey; Ezequiel Alvarez
Journal:  Vasc Health Risk Manag       Date:  2013-07-25

8.  Endothelium-Dependent Vasorelaxant Effects of Dealcoholized Wine Powder of Wild Grape (Vitis coignetiae) in the Rat Thoracic Aorta.

Authors:  Sang Keun Ha; Ho-Young Park; Mee-Ra Ryu; Yoonsook Kim; Yongkon Park
Journal:  Evid Based Complement Alternat Med       Date:  2016-10-20       Impact factor: 2.629

Review 9.  Therapeutic uses of epicatechin in diabetes and cancer.

Authors:  Layth Abdulmajeed Abdulkhaleq; Mohammed Abdulrazzaq Assi; Mohd Hezmee Mohd Noor; Rasedee Abdullah; Mohd Zamri Saad; Yun Hin Taufiq-Yap
Journal:  Vet World       Date:  2017-08-06

10.  Differential regulation of adipose tissue and vascular inflammatory gene expression by chronic systemic inhibition of NOS in lean and obese rats.

Authors:  Jaume Padilla; Nathan T Jenkins; Pamela K Thorne; Kasey A Lansford; Nicholas J Fleming; David S Bayless; Ryan D Sheldon; R Scott Rector; M Harold Laughlin
Journal:  Physiol Rep       Date:  2014-02-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.